Sanofi Genzyme backs further out of deal with Voyager
Having already backed out of an option on a Parkinson’s disease program in 2017, Sanofi Genzyme is now pulling further out of its collaboration with USA-based Voyager Therapeutics (Nasdaq: VYGR), as the companies yesterday announced a restructuring of their gene therapy relationship.
Under the terms of the agreement, Voyager re-gains worldwide rights to the VY-HTT01 Huntington’s disease program and ex-US rights to the VY-FXN01 Friedreich’s ataxia program. The ex-US rights to VY-FXN01 are, in turn, transferred from Voyager to Neurocrine Biosciences (Nasdaq: NBIX) under the terms of the collaboration agreement between Voyager and Neurocrine Biosciences announced in January 2019.
Despite the mixed news, Voyager’s shares, which fell 3.4% pre-market, ended trading on Monday up 10.35% at $26.75. Sanofi was up 2.7% at 77.52 euros by late afternoon today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze